Drug Type Peptide drug conjugates |
Synonyms- |
Target |
Action modulators, inhibitors |
Mechanism KRAS modulators(GTPase KRas modulators), PTEN modulators(Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN modulators), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H29NO11 |
InChIKeyAOJJSUZBOXZQNB-TZSSRYMLSA-N |
CAS Registry23214-92-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | - | 10 Dec 2024 |